Literature DB >> 21601197

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation.

Lawrence Engmann1, Jonathan Romak, John Nulsen, Claudio Benadiva, John Peluso.   

Abstract

OBJECTIVE: To evaluate viability of luteinized granulosa cells obtained from patients triggered with either GnRH agonist or hCG and to assess the secretion of steroids and vascular endothelial growth factor (VEGF) by cultured luteinized granulosa cells in the presence or absence of hCG.
DESIGN: Prospective, randomized controlled trial.
SETTING: University-based fertility center. PATIENT(S): A subset of patients who underwent a randomized trial involving GnRH agonist trigger after GnRH antagonist protocol vs. hCG trigger after pituitary suppression with GnRH agonist protocol. INTERVENTION(S): In vitro fertilization cycles. MAIN OUTCOME MEASURE(S): Proportion of apoptosis; basal and hCG-induced secretion of E(2), P, and VEGF by luteinized granulosa cells; follicular-fluid VEGF and luteal-phase serum E(2), P, and plasma VEGF concentrations. RESULT(S): There were no differences in the proportion of granulosa/luteal cell apoptosis, follicular-fluid or luteal-phase plasma VEGF concentration, or basal culture media E(2), P, and VEGF concentrations between the two groups. Addition of hCG to the culture media significantly increased the P concentration in both groups, but there were no changes in E(2) or VEGF concentrations. Serum E(2) levels were lower at 5 and 9 days after GnRH agonist compared with hCG trigger. CONCLUSION(S): The granulosa/luteal cells obtained on the day of oocyte retrieval after GnRH agonist trigger are still viable and have the capacity to respond to hCG by increasing the secretion of steroids.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21601197     DOI: 10.1016/j.fertnstert.2011.04.071

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

1.  Inhibition of neddylation causes meiotic arrest in mouse oocyte.

Authors:  Mo Yang; Yimei Jin; Siying Fan; Xiaoling Liang; Jialin Jia; Zhongzhou Tan; Tao Huang; Yuan Li; Teng Ma; Mo Li
Journal:  Cell Cycle       Date:  2019-05-21       Impact factor: 4.534

2.  PHF1 is required for chromosome alignment and asymmetric division during mouse meiotic oocyte maturation.

Authors:  Yi Qu; Yang Wang; Jie Qiao
Journal:  Cell Cycle       Date:  2018-11-11       Impact factor: 4.534

3.  Does gonadotropin-releasing hormone agonist cause luteolysis by inducing apoptosis of the human granulosa-luteal cells?

Authors:  Noa Gonen; Robert F Casper; Andrea Jurisicova; Yuval Yung; Moran Friedman-Gohas; Raoul Orvieto; Jigal Haas
Journal:  J Assist Reprod Genet       Date:  2021-05-24       Impact factor: 3.357

4.  GnRH agonist vs. hCG for triggering of ovulation--differential effects on gene expression in human granulosa cells.

Authors:  Jigal Haas; Libby Ophir; Eran Barzilay; Gil M Yerushalmi; Yuval Yung; Alon Kedem; Ettie Maman; Ariel Hourvitz
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

5.  The dual trigger study: Rationale and study design of a prospective double-blind randomized clinical trial comparing pregnancy rates after co-administration of low dose hCG at the time of GnRH agonist trigger or 35 h later for the prevention of OHSS.

Authors:  Daniel Griffin; Claudio Benadiva; Tara Budinetz; Carolina Sueldo; Andrea DiLuigi; John Nulsen; Lawrence Engmann
Journal:  Contemp Clin Trials Commun       Date:  2017-08-17

6.  Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.

Authors:  L L Engmann; B S Maslow; L A Kaye; D W Griffin; A J DiLuigi; D W Schmidt; D R Grow; J C Nulsen; C A Benadiva
Journal:  J Ovarian Res       Date:  2019-01-26       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.